Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884874 | 1.00 | MAPT (0.40) | MAPTL3MBTL1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL1888752 | 0.85 | L3MBTL1 (0.41) | MAPTL3MBTL1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL1884816 | 0.85 | MAPT (0.36) | MAPTL3MBTL1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL1884157 | 0.85 | L3MBTL1 (0.41) | MAPTL3MBTL1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL1884547 | 0.85 | MAPT (0.36) | MAPTL3MBTL1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL1884906 | 0.83 | MAPT (0.42) | MAPTL3MBTL1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL1891741 | 0.83 | MAPT (0.42) | MAPTL3MBTL1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL1888802 | 0.82 | MAPT (0.41) | MAPTL3MBTL1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL1886204 | 0.82 | MAPT (0.41) | MAPTL3MBTL1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL1884778 | 0.82 | MAPT (0.41) | MAPTL3MBTL1SMN1; SMN2RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150030937-A1 | Nonaqueous Electrolyte for Lithium Ion and Lithium Metal Batteries | ENERIZE CORPORATION (US) | 2015-01-29 | — | — | US | claimed |
| US-20150030937-A1 | Nonaqueous Electrolyte for Lithium Ion and Lithium Metal Batteries | ENERIZE CORPORATION (US) | 2015-01-29 | — | — | US | disclosed |
| US-20110104574-A1 | Nonaqueous electrolyte for lithium Ion and lithium metal batteries | ENERIZE CORPORATION (US) | 2011-05-05 | — | — | US | disclosed |
| US-7494985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | APEH, AASDHPPT, AGPS | MAPT 4107/4885L3MBTL1 2410/4885SMN1; SMN2 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.